Catalan biopharmaceutical firm Mitelos, a CataloniaBio & HealthTech member, has signed a deal with Biolab Pharma to commercialise its Otiblock® spray in Brazil. 

Otiblock® is an innovative therapeutic solution that eliminates earwax while maintaining proper pH levels thanks to its oil-free formulation. Otiblock® is particularly beneficial to people prone to relapse, such as those with narrow ear canals or who use hearing aids or earphones.

"We are selling Otiblock® in 12 countries and we plan to launch the product in three more. Our priority is to find distributors in France, Germany, Turkey and Scandinavia," explains Joaquim Colomé, CEO of Mitelos.

Founded in 1997, Biolab Pharma is one of the biggest commercial laboratories in the Brazilian market, with a portfolio of 170 drugs and healthcare products.

You may also be interested in:

• Mitelos and Faes Farma reach deal to market new spray for external otitis
• Mitelos and New Mark to market Otiblock® in the Arab Emirates